A phase I study of peginterferon alfa-2b (PEG-INTRON) with sorafenib (Nexavar) in patients with unresectable or metastatic clear cell renal carcinoma (RCC).

Trial Profile

A phase I study of peginterferon alfa-2b (PEG-INTRON) with sorafenib (Nexavar) in patients with unresectable or metastatic clear cell renal carcinoma (RCC).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Sorafenib
  • Indications Renal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 May 2013 Lead trial center changed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top